BIO B — Bio-Rad Laboratories Share Price
Last trade - 00:00- $9.75bn
- $9.34bn
- $2.58bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.36 | ||
| Price to Tang. Book | 1.51 | ||
| Price to Free Cashflow | 27.63 | ||
| Price to Sales | 3.77 | ||
| EV to EBITDA | 43.28 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.51% | ||
| Return on Equity | 3.11% | ||
| Operating Margin | 1.82% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,922.55 | 2,802.25 | 2,671.26 | 2,566.5 | 2,583.2 | n/a | n/a | 0.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +12.85 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Directors
- Norman Schwartz CHM (71)
- Ilan Daskal CFO (55)
- Andrew Last COO (61)
- Timothy Ernst EVP (61)
- Michael Crowley EVP (59)
- Giovanni Magni EVP (64)
- Simon May EVP
- Dara Wright EVP (45)
- Ronald Hutton VPR (63)
- Gregory Hinckley LED (73)
- Alice Schwartz DRC (94)
- Jeffrey Edwards IND (61)
- Melinda Litherland IND (63)
- Arnold Pinkston IND (62)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- March 10th, 1975
- Public Since
- March 17th, 1980
- No. of Shareholders
- 217
- No. of Employees
- 7,450
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 26,738,175
- Address
- 1000 ALFRED NOBEL DR, HERCULES, 94547
- Web
- https://www.bio-rad.com/
- Phone
- +1 3026587581
- Contact
- Ruben Argueta
- Auditors
- KPMG LLP
Latest News for BIO B
Similar to BIO B
Abbott Laboratories
New York Stock Exchange
Accendra Health
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
As of Today at 01:37 UTC, shares in Bio-Rad Laboratories are trading at $364.15. This share price information is delayed by 15 minutes.
Shares in Bio-Rad Laboratories last closed at $364.15 and the price had moved by +27.83% over the past 365 days. In terms of relative price strength the Bio-Rad Laboratories share price has outperformed the S&P500 Index by +9.42% over the past year.
There is no consensus recommendation for this security.
Find out moreBio-Rad Laboratories does not currently pay a dividend.
Bio-Rad Laboratories does not currently pay a dividend.
Bio-Rad Laboratories does not currently pay a dividend.
To buy shares in Bio-Rad Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $364.15, shares in Bio-Rad Laboratories had a market capitalisation of $9.75bn.
Here are the trading details for Bio-Rad Laboratories:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BIO B
Based on an overall assessment of its quality, value and momentum Bio-Rad Laboratories is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bio-Rad Laboratories. Over the past six months, its share price has outperformed the S&P500 Index by +20.68%.
As of the last closing price of $364.15, shares in Bio-Rad Laboratories were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bio-Rad Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $364.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bio-Rad Laboratories' management team is headed by:
- Norman Schwartz - CHM
- Ilan Daskal - CFO
- Andrew Last - COO
- Timothy Ernst - EVP
- Michael Crowley - EVP
- Giovanni Magni - EVP
- Simon May - EVP
- Dara Wright - EVP
- Ronald Hutton - VPR
- Gregory Hinckley - LED
- Alice Schwartz - DRC
- Jeffrey Edwards - IND
- Melinda Litherland - IND
- Arnold Pinkston - IND